-
公开(公告)号:US20130115194A1
公开(公告)日:2013-05-09
申请号:US13667197
申请日:2012-11-02
申请人: Daniel D. LONG , Robert Murray MCKINNELL , Lan JIANG , Mandy LOO , Kassandra LEPACK , Lori Jean VAN ORDEN , Gavin OGAWA , Xiaojun HUANG , Weijiang ZHANG
发明人: Daniel D. LONG , Robert Murray MCKINNELL , Lan JIANG , Mandy LOO , Kassandra LEPACK , Lori Jean VAN ORDEN , Gavin OGAWA , Xiaojun HUANG , Weijiang ZHANG
IPC分类号: C07D401/14 , C07D405/14 , C07D413/14 , C07D417/14 , A61K31/496 , A61P31/14 , A61K31/541 , C07F5/02 , A61K38/21 , A61K31/7056 , A61K31/7052 , C07D491/113 , A61K31/5377
CPC分类号: A61K31/496 , A61K31/5377 , A61K31/541 , A61K45/06 , C07D401/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D491/113
摘要: The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.
摘要翻译: 本发明提供式(I)化合物:其中变量在说明书中定义,或其药学上可接受的盐,其是丙型肝炎病毒的复制抑制剂。 本发明还提供包含这些化合物的药物组合物,使用这些化合物治疗丙型肝炎病毒感染的方法,以及可用于制备这些化合物的方法和中间体。
-
公开(公告)号:US20120114600A1
公开(公告)日:2012-05-10
申请号:US13288216
申请日:2011-11-03
申请人: Robert Murray McKINNELL , Daniel D. LONG , Lori Jean VAN ORDEN , Lan JIANG , Mandy LOO , Daisuke Roland SAITO , Shella ZIPFEL , Eric L. Stangeland , Kassandra Lepack , Gavin Ogawa
发明人: Robert Murray McKINNELL , Daniel D. LONG , Lori Jean VAN ORDEN , Lan JIANG , Mandy LOO , Daisuke Roland SAITO , Shella ZIPFEL , Eric L. Stangeland , Kassandra Lepack , Gavin Ogawa
IPC分类号: A61K38/21 , C07D401/14 , C07D405/14 , C07D413/14 , C07D498/10 , A61K31/496 , C07D417/14 , A61K31/506 , A61K31/497 , A61K31/5377 , A61K31/517 , A61K31/7056 , A61K31/7052 , A61P31/14 , C07D403/14
CPC分类号: C07D401/14 , A61K31/496 , A61K45/06 , C07D403/14
摘要: The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.
摘要翻译: 本发明提供式(I)化合物:其中变量在说明书中定义,或其药学上可接受的盐,其是丙型肝炎病毒的复制抑制剂。 本发明还提供包含这些化合物的药物组合物,使用这些化合物治疗丙型肝炎病毒感染的方法,以及可用于制备这些化合物的方法和中间体。
-